Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1261-1280 of 2,251 trials

Advanced Breast Cancer: Trastuzumab Deruxtecan vs. CDK4/6 Inhibitors

We are studying whether trastuzumab deruxtecan is more effective than a combination of CDK4/6 inhibitors and endocrine therapy for patients with HR-positive, HER2-low advanced breast cancer. This research aims to improve treatment options for this specific group of patients.

Locally Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOncology

Small-Cell Lung Cancer: Durvalumab and Olaparib Maintenance Therapy

We are studying the effects of a combination of durvalumab and olaparib for patients with HRD-positive extensive disease small-cell lung cancer after initial treatment. The goal is to see if this maintenance therapy improves outcomes and is safe for patients.

Extensive Stage Small Cell Lung Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

Duchenne Muscular Dystrophy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyNeurologyPediatrics

Anesthesia in Young Children: Low-Dose vs. Standard Sevoflurane

We are comparing the effects of low-dose sevoflurane combined with dexmedetomidine and remifentanil against standard sevoflurane anesthesia on cognitive development in children under 2 years old. The goal is to see which method supports better brain development as they grow.

General Anesthesia in Young Children>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Advanced Cancer: JK06 Antibody Drug

We are testing a new drug called JK06 for patients with advanced cancer that cannot be removed by surgery. The study aims to evaluate its safety and how well it may work in treating this type of cancer.

Unresectable, Locally Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboOncology

Soft Tissue Sarcomas: INT230-6 Treatment Study

We are investigating a new treatment for adults with advanced soft tissue sarcomas to see if it works better than standard care. The study will also look at side effects and quality of life for participants.

Myxoid LiposarcomaDedifferentiated LiposarcomaRound Cell Liposarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Organ Transplantation: Custodiol-N vs. Custodiol Solution

We are studying a new preservation solution for kidney, liver, and pancreas transplants to see if it works as well as the current standard. This research may help improve outcomes for transplant recipients.

Organ Transplant Candidates>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyHepatologyInternal MedicineNephrologyOrthopedics and Traumatology

Psoriatic Arthritis: Guselkumab for Enthesitis

We are studying whether Guselkumab can help reduce inflammation in patients with psoriatic arthritis who have not received prior treatments. This trial focuses on those with ultrasound-confirmed enthesitis.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Bevacizumab vs. Corticosteroids for Cerebral Radiation Necrosis

We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.

Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

ANCA Vasculitis: Stopping Immunosuppressive Therapy

We are studying whether stopping immunosuppressive therapy helps patients with ANCA vasculitis and end-stage renal disease avoid serious health issues compared to continuing treatment.

End-stage Renal DiseaseANCA Vasculitis>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNephrologyRheumatology

CRISPR CAR Therapy for Blood and Solid Cancers

We are studying the long-term safety and effectiveness of CRISPR CAR cellular therapies in patients with hematological and solid malignancies. This research aims to provide insights into how well this treatment works over time.

Solid TumorsHematologic Malignancies>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Pancreatic Cancer: New Electroporation Treatments

We are studying the effects of three innovative treatments for pancreatic cancer to see if they improve quality of life and survival. This includes assessing pain levels and weight loss in patients.

Unresectable Pancreatic Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Liver Cancer: Hyperpolarized Pyruvate MRI Study

We are exploring whether a new MRI technique can help detect small liver tumors earlier in people at risk for hepatocellular carcinoma. This may improve early diagnosis and treatment options.

Primary Liver Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

Chronic Kidney Disease: Ultra-Sensitive MRI Study

We are investigating how advanced MRI can detect metabolic changes in patients with chronic kidney disease and polycystic kidney disease. This research may help improve diagnosis and treatment monitoring.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)Chronic Kidney Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Glioblastoma: Dendritic Cell Vaccine Study

We are testing a personalized vaccine made from your own immune cells and tumor tissue for patients with glioblastoma. The study aims to see if this treatment can improve safety and help patients live longer without disease progression.

Glioblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Plaque Psoriasis: TAK-279 Oral Medication

We are studying a new daily oral treatment for people with moderate-to-severe plaque psoriasis. The trial will help us understand its long-term safety and effectiveness.

Plaque Psoriasis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Cochlear Implant Surgery: Testing VSF1.01 Treatment

We are investigating the safety of a new treatment for patients receiving cochlear implants. This study aims to see if it can reduce surgery-related trauma and improve hearing outcomes.

Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboOtolaryngology

Colon Cancer: Neoadjuvant Dostarlimab Treatment

We are studying the effects of Dostarlimab in patients with untreated Stage III colon cancer. This trial aims to understand how well the treatment works and its safety before surgery.

Resectable Colon Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

CIDP Treatment: Rituximab Study

We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Triple-Negative Breast Cancer: NECVAX-NEO1 Treatment

We are studying the safety and effects of NECVAX-NEO1 added to standard PD-1 inhibitor therapy for patients with triple-negative breast cancer. This trial aims to see if the new treatment can enhance cancer response and improve outcomes.

Triple Negative Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology